Among the 50 stocks in the Nifty index, 42 were trading in the green, while 8 were in the red. Shares of Vodafone Idea, ...

Glenmark Pharma: The drug maker reported consolidated revenue of ₹3,256 crore, up 6.3% year-on-year (YoY) from ₹3,063 crore in the same quarter last year. NTPC: The PSU has posted a 22.6% sequential ...

Q4 results: Aurobindo Pharma, Firstcry parent Brainbees Solutions, KEC International, Nazara Technologies, Akums Drugs and Pharmaceuticals, Awfis Space Solutions, Blue Dart Express, General Insurance ...

Net profit of Glenmark Pharmaceuticals reported to Rs 4.65 crore in the quarter ended March 2025 as against net loss of Rs 1218.28 crore during the previous quarter ended March 2024. ... Sayaji Hotels ...

On May 23, 2025, multiple companies including JSW Steel and Glenmark Pharmaceuticals will announce their Q4 financial results for the quarter ending March 31, 2025, as per the BSE calendar.

Glenmark Pharmaceuticals: Ichnos Glenmark Innovation received USFDA fast-track status for ISB 2001, ... Indian Hotels Q4 Highlights (Consolidated, YoY) Revenue up 27.3% to Rs 2,425 crore versus Rs ...

Indian Hotels Company The firm had a net profit of Rs 438.33 crore on a consolidated basis in the year-ago period. Its revenue from operations rose 27.3% to Rs 2,425.14 crore from Rs 1,905.34 ...

Glenmark is set to launch a generic version of Teva’s Adderall tablets in strengths ranging from 5 mg to 30 mg, with distribution set to begin in May 2025. The company will launch ...

FDA inspectors found serious problems at a Glenmark factory in India that manufactured the recalled drugs. Another medication made there has been tied to deaths of U.S. patients.

NEW DELHI: Drug makers Glenmark, Sun Pharma and Zydus are recalling products in the US for manufacturing issues, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report.